October 17, 2024
FDA issues IV fluids emergency guidance
The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage.
October 15, 2024
FDA reconsiders on tirzepatide, big questions remain
After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list.
October 11, 2024
Tirzepatide fallout in The Hill
The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.
October 11, 2024
Reporter briefing: Patient impacts of tirzepatide shortage resolution
APC's media briefing shared compounders' first-hand stories with more than 30 reporters from across the country.
October 11, 2024
Be sure your marketing follows these best practices
APC's new guide will help you stay on the right side of laws and regs.
October 11, 2024
A fake survey from a pharma-funded organization
What the Partnership for Safe Medicines released "Ain't a legitimate survey."
October 11, 2024
Lots of letters
On the compounding front, the FDA’s inbox is getting quite a workout lately.
October 11, 2024
Slick new dosing pen for compounders
Love Lifesciences’ UniPen injector pen is not only a Very Big Deal, it's available at a discount for APC PFM members.
October 10, 2024
Echoing our position
Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.
October 10, 2024
Wired story isn’t perfect, but…
This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.
October 9, 2024
Wired focuses on GLP-1 patient fallout
Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.
October 9, 2024
Quartz mentions APC
Not a big deal, but it shows we're getting media coverage across the spectrum.
October 9, 2024
San Diego news radio focuses on GLP-1 price
It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻
October 9, 2024
CNN gets it spot on
The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.
